Research
What the documents actually say.
Two things get written here. One is an investigation, run over the seller record this site maintains, into a question the market would rather leave vague. The other is a close reading of the trial literature on a specific drug or risk. Neither is a news summary, and neither goes out with a number we could not trace to the document it came from.
Research formats
Related tools
- Scientific deep-dive7 min · 15 sources
Trulicity for Weight Loss: How Much at Each Dose
AWARD-11 found weight loss of 3.0, 3.8 and 4.6 kg on Trulicity 1.5, 3 and 4.5 mg at 36 weeks. Head to head in SUSTAIN 7, Ozempic 1 mg took off 6.5 kg against 3.0 kg for Trulicity 1.5 mg. All of this comes from people with type 2 diabetes. No published randomized trial has tested dulaglutide for weight without diabetes.
Read the analysis→ - Scientific deep-dive7 min · 14 sources
What Is Phentermine? Uses, Label Limits and How It Compares
Phentermine is a daily stimulant pill, related to amphetamine and federally controlled under Schedule IV. It remains the most prescribed obesity drug in the US, though its label approves only a few weeks and long-term research is thin. A 24-month randomized trial, LEAP, finished in September 2026 and had posted no results as of November 10, 2026.
Read the analysis→ - Data investigation8 min · 20 sources
Best Injection for Weight Loss? Every Approved Shot, Ranked on Trial Data
On weight alone the answer is tirzepatide: 20.9% in the Zepbound label and 20.2% vs 13.7% against semaglutide. Semaglutide has the licensed heart indication, and tirzepatide's obesity outcomes trial runs into 2027. CagriSema lost its head-to-head, and retatrutide is not approved.
Read the analysis→ - Scientific deep-dive6 min · 21 sources
When to Take Berberine: Before Meals, at Night and the Doses Tested
Advice to take berberine before meals or at bedtime goes beyond the evidence. Trials used before-meal and after-meal schedules alike, nobody has compared them head to head, and the single food-effect study used a cough syrup.
Read the analysis→ - Scientific deep-dive8 min · 21 sources
How to Tighten Skin After Weight Loss: Radiofrequency, Ultrasound and Surgery
Skin stretched for years changes structurally, and devices measure their results in centimeters and millimeters. One review names a BMI over 30 and excessive laxity as reasons for caution with ultrasound. Surgery improves quality of life, though GLP-1 use may raise some wound risks.
Read the analysis→ - Data investigation7 min · 10 sources
Does Vermont Medicaid Cover Wegovy or Zepbound? Heart, MASH and Sleep Apnea Only
Vermont Medicaid will not pay for weight loss. Wegovy injection is preferred for people without diabetes who have a BMI over 27 and a past heart attack, stroke or artery disease, or who have MASH with F2 or F3 fibrosis. Zepbound is preferred for sleep apnea with an AHI over 15, and CPAP only has to be prescribed.
Read the analysis→ - Data investigation6 min · 17 sources
Rhode Island Medicaid and GLP-1s: Weight-Loss Coverage Ended October 1, 2026
The cutoff has passed. Weight-loss approvals ended on September 30, 2026 with no grandfathering in the documents. What remains depends on the reason on the prescription, and the budget text and the state memo do not read alike.
Read the analysis→ - Data investigation8 min · 16 sources
Does New Hampshire Medicaid Still Cover Wegovy or Zepbound? The 2026 Rules
Since January 2026, New Hampshire Medicaid has refused GLP-1s prescribed only for weight loss. Wegovy for heart disease and Zepbound for sleep apnea need a failed three-month diet and no diabetes; Wegovy for MASH needs a liver specialist, an MRI fat scan and a statin. Orlistat and phentermine are still covered.
Read the analysis→ - Data investigation7 min · 11 sources
Does MaineCare Cover Wegovy or Zepbound? Heart, Liver and Sleep Apnea Rules
MaineCare's drug list says weight-loss drugs are not covered, and phentermine and Xenical are off the list too. With prior authorization it pays for Wegovy in adults with a BMI over 27 after a stroke, heart attack or symptomatic artery disease, or with MASH at F2 to F3 under a specialist, approved three months at a time. Zepbound needs a recent sleep study, a failed CPAP trial, three months of lifestyle change and no diabetes.
Read the analysis→ - Data investigation8 min · 13 sources
Does Delaware Medicaid Cover Wegovy and Zepbound? Yes, With a Health-Condition Rule
Delaware Medicaid covers Wegovy, Zepbound and Saxenda for weight loss with prior authorization. Adults need a BMI over 30, or over 27, plus at least one listed condition such as high blood pressure or sleep apnea, and must keep at least 5% of their weight off to renew. Teens qualify at the 95th BMI percentile.
Read the analysis→ - Data investigation9 min · 18 sources
Medicaid Managed Care and Wegovy: Why Your Plan Often Doesn't Set the GLP-1 Rule
Your Medicaid plan follows your state on weight-loss GLP-1s. Plans must cover at least what fee-for-service covers and meet the federal drug rules, and many states go further: New York and California pay drugs outside the plans, Ohio and Indiana use one list for everyone, and North Carolina bars plans from adding criteria. Where plans may write their own, as in DC, renewal tests for Zepbound in sleep apnea differ by plan.
Read the analysis→ - Data investigation7 min · 12 sources
Does Wyoming Medicaid Cover Wegovy or Zepbound? The Sleep Apnea, MASH and Heart Routes
Wyoming Medicaid excludes anorexiant products and lists Wegovy and Zepbound only for other conditions. Zepbound is approved for adults with obesity and an AHI above 15, with renewals tied to 5% weight loss and a repeat sleep study. Wegovy needs only a MASH diagnosis, or a BMI of 27 or more with a prior heart attack, stroke or artery disease.
Read the analysis→ - Data investigation8 min · 12 sources
West Virginia Medicaid and Wegovy or Zepbound: The Heart, Liver and Sleep Apnea Routes
West Virginia Medicaid lists weight-loss drugs as a benefit exclusion. With prior authorization it pays for Wegovy after a heart event in adults without diabetes, for Wegovy in MASH confirmed by biopsy or a liver stiffness scan, and for Zepbound in sleep apnea with an AHI of 15 or more. Pharmacy sits outside the managed care plans, so the state's rules apply to every member.
Read the analysis→ - Data investigation8 min · 12 sources
Does Washington Apple Health Cover Wegovy or Zepbound? The Three Medical Routes
Apple Health excludes weight-loss drugs by rule. With prior authorization, adults without diabetes can get Wegovy for a broad list of heart and artery conditions at a BMI of 27 or more, or for MASH, and Zepbound for sleep apnea even if they declined PAP. People with diabetes can request Mounjaro for sleep apnea.
Read the analysis→ - Data investigation7 min · 8 sources
Does TennCare Cover Wegovy and Zepbound? Yes, for Obesity, With a 5% Renewal Test
TennCare is one of the few Medicaid programs that pays for Wegovy and Zepbound to treat obesity. Adults qualify with a BMI above 30, or above 27 plus a related condition; Wegovy is open from age 12. Renewal needs 5% weight loss, and the sleep apnea route asks for three months of failed CPAP.
Read the analysis→ - Data investigation7 min · 13 sources
South Dakota Medicaid and Wegovy or Zepbound: No Weight-Loss Coverage, Three PA Routes
South Dakota Medicaid's pharmacy manual excludes weight-loss agents. Prior authorization can still approve Wegovy for people without diabetes who have had a heart attack, stroke or artery disease or who have MASH with F2 or F3 fibrosis. A separate form covers Zepbound when sleep apnea is moderate to severe, and it asks no CPAP question.
Read the analysis→ - Data investigation8 min · 8 sources
Does the Oregon Health Plan Cover Wegovy or Zepbound? OHP's 2026 GLP-1 Rules
The Oregon Health Plan will not pay for Wegovy or Zepbound when an adult's only goal is weight loss. It covers Wegovy for established heart disease or MASH, plus Zepbound for sleep apnea, each after a BMI check, three months of a provider-run weight plan and a diabetes screen, with no CPAP step. Members eligible for EPSDT, mostly those under 21, can be approved for a weight drug the FDA allows at their age.
Read the analysis→ - Data investigation8 min · 9 sources
Does North Dakota Medicaid Cover Wegovy? The Ozempic-First Routes Explained
North Dakota Medicaid says GLP-1s are not covered for weight loss. It pays for semaglutide to cut heart risk in adults aged 55 to 74 with a BMI from 27 to under 35 and no diabetes, for MASH with F2 to F3 fibrosis, and for sleep apnea after six failed months of CPAP. Ozempic comes first on each route, and phentermine needs only an obesity diagnosis code.
Read the analysis→ - Data investigation7 min · 15 sources
Does New Mexico Medicaid Cover Wegovy? Why Phentermine Is In and GLP-1s Are Out
New Mexico Medicaid will not pay for Wegovy, Zepbound or Saxenda, and the state publishes no exception for heart disease, sleep apnea or MASH. It does cover phentermine, orlistat and four other older diet drugs with prior authorization at a BMI over 40, or over 35 with a related condition. Diabetes GLP-1s sit outside the 2026 statewide drug list, so each Turquoise Care plan sets its own rules.
Read the analysis→ - Data investigation8 min · 14 sources
Does Nebraska Medicaid Cover Wegovy or Zepbound? Heritage Health GLP-1 Rules
Nebraska's pharmacy rules exclude drugs for weight control. With prior authorization, Wegovy is covered for heart risk in adults 45 to 74 without diabetes or for MASH, and Zepbound for sleep apnea once CPAP and an oral appliance have failed. Every route needs a six-month supervised weight program first.
Read the analysis→ - Data investigation7 min · 11 sources
Does Montana Medicaid Cover Wegovy or Zepbound? Heart, MASH and Sleep Apnea Rules
Montana lists weight-loss drugs as not covered. Adults without type 2 diabetes can still get Wegovy for heart disease or MASH with a specialist involved, and Zepbound for sleep apnea, but only after six months on PAP that leaves the AHI at 15 or higher. People with diabetes use Ozempic, Trulicity or Victoza.
Read the analysis→ - Data investigation8 min · 20 sources
Does Louisiana Medicaid Cover Wegovy or Zepbound? Act 898 and Today's Rules
As of November 2026 Louisiana Medicaid excludes weight-loss drugs except orlistat. Act 898, signed June 9, 2026, orders coverage without step therapy, yet it starts only when the legislature appropriates money, and the 2026 budget acts carry none. Wegovy is paid for heart risk from age 45, at a BMI from 27 up, for people without diabetes, and Zepbound is paid for sleep apnea with clinical authorization.
Read the analysis→ - Data investigation7 min · 10 sources
Does Idaho Medicaid Cover Wegovy or Zepbound? Obesity Drugs Are Excluded by Rule
Idaho Medicaid does not pay for Wegovy, Zepbound or Saxenda to treat obesity; its benefit rules exclude those uses and its drug list has no anti-obesity class. Ozempic pens, Trulicity and Victoza are preferred for type 2 diabetes with only a diagnosis code. Adults at a BMI of 30 and above can get up to $200 a year toward a weight program.
Read the analysis→ - Data investigation7 min · 14 sources
Does Hawaii Med-QUEST Cover Wegovy or Zepbound? Not for Weight Loss
Hawaii Med-QUEST will not pay for Wegovy, Zepbound or Saxenda as weight-loss drugs; AlohaCare's QUEST page lists weight-loss drugs as not covered. House Bill 2456 and Senate Bill 3195 would have required coverage without prior authorization in 2026. No published QUEST criteria for heart risk, MASH or sleep apnea could be found.
Read the analysis→
Every research article, A to Z (492)
- 5-Amino-1MQ: What the Evidence Shows, and What FDA Has Said
- 503A vs 503B Compounding Pharmacies: Who Oversees Your Compounded GLP-1
- A Benefit Nobody Observed
- A Biologic Plus Tirzepatide for Psoriasis
- A Biomarker Is Not an Outcome
- A Composite Is Only Its Components
- A Drug to Protect Muscle
- A Pill to Hold What the Injection Lost
- A Proportion That Rises by Itself
- A Quarter the Odds of Being Offered It
- A Trial About the Measuring Instrument
- A Weight Drug for Having Too Little Fat
- Acanthosis Nigricans: What Clears the Dark Patches, and What GLP-1s Do
- Adderall and a GLP-1: Taking an ADHD Stimulant With Ozempic or Zepbound
- Akkermansia muciniphila: What the Human Trials Show About Weight and GLP-1
- Amycretin: A 24% Weight Figure, and the Trial It Came From
- An Oral Pill in a Diabetes Population
- Another Molecule You Cannot Buy
- Antidepressants and a GLP-1: Ozempic, Wellbutrin, Lexapro and What the Labels Say
- Antipsychotics and Metabolic Harm
- AOD-9604: What the Evidence Shows
- Appetite Suppressants: Every FDA-Approved Drug and What Its Label Shows
- Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show
- Are Peptides Legal? What FDA’s 2026 Lists Say
- Are Peptides Safe? Approved, Compounded and Research-Use-Only Compared
- Are Peptides Steroids? How They Differ in Chemistry, US Law and Sport
- Berberine for Weight Loss: The Randomized Trial and the Meta-Analyses
- Best Injection for Weight Loss? Every Approved Shot, Ranked on Trial Data
- Beyond BMI: Who Actually Needs Treatment
- Beyond the Scale: Blood Pressure, Lipids and What Else Changes
- Bimagrumab Plus Semaglutide: The Muscle Question
- Blood Thinners and a GLP-1: Warfarin, Eliquis, Xarelto With Ozempic or Mounjaro
- Blurred Vision on Ozempic or Mounjaro: Causes, How Long It Lasts, When It's Urgent
- Bone Density on a GLP-1: The Trial That Compared It Against Exercise
- BPC-157 and TB-500 Together: Blends, Stacks and the HHS Single-Ingredient Rule
- BPC-157 Capsules: Oral BPC-157, the HHS Policy and What Is Known About Absorption
- BPC-157 Dosage: What the Human Studies Actually Gave
- BPC-157 FDA Status: What the Agency Put on the Record
- BPC-157 for Knee, Tendon and Back Pain: The Human Evidence
- BPC-157 Side Effects: What Is Known in People, and What Nobody Has Measured
- BPC-157 vs TB-500: Two Recovery Peptides, One With No Human Studies
- BPC-157, MOTS-c and Other Peptides With Semaglutide or Tirzepatide
- Buffalo Hump: Causes, Cushing's Signs, and Whether Weight Loss Shrinks It
- Burping, Reflux and Gas on a GLP-1: The Label's Widest Gap
- Buying a GLP-1 With No Insurance: What It Really Costs
- Buying Tirzepatide as a Research Chemical: What "Research Use Only" Really Means
- Cagrilintide: What the Evidence Shows, and Why You Can't Buy It
- CagriSema Beat Semaglutide. By How Much?
- Can Ozempic or Mounjaro Cause Liver Damage? Liver Enzymes Evidence Review
- Can You Boost GLP-1 Naturally With Food?
- Can You Donate Blood on Ozempic, Wegovy, Mounjaro or Zepbound?
- Can You Lower the Dose and Keep the Weight Off?
- Cancer Risk in People Without Diabetes
- Capsaicin and Capsinoids for Weight Loss: Eight Measures, Eight Nulls
- CGM for Weight Loss Without Diabetes: What the Trials Show
- CJC-1295 and Ipamorelin: What FDA Recorded
- CJC-1295 vs Ipamorelin: How They Differ, and What FDA Recorded on Each
- Coffee on Ozempic, Wegovy or Mounjaro: What the Labels and Studies Say
- Collagen Peptides: What the Trials Show for Skin, Joints, Bone and Muscle
- Colorado Medicaid and GLP-1s: What Health First Colorado Will and Won't Pay For
- Comparing Trials That Never Met
- Compounded GLP-1s and the Adverse Event Reports
- Compounded Semaglutide and Tirzepatide Are Ending: What to Do Next
- Compounded Semaglutide vs Ozempic and Wegovy: What Is Actually Different
- Compounded Semaglutide: Is a Prescription Required?
- Compounded Tirzepatide Side Effects: The Drug, and the Vial
- Compounded Tirzepatide vs Zepbound: Same Molecule, Different Product
- Constipation on a GLP-1: What the Labels Report and What Actually Helps
- Creatine on a GLP-1: The Trial Nobody Has Run
- CVS Caremark and Zepbound: Coverage Is Back, but Check Your Plan
- Danuglipron: The Oral GLP-1 That Worked, and That 6 in 10 Did Not Finish
- Diastasis Recti and Weight Loss: What GLP-1s, Exercise and Surgery Change
- Dizzy on a GLP-1? The Blood-Pressure Question the Labels Skip
- Do GLP-1 Drugs Reduce Dementia Risk? Three Analyses, Three Answers
- Do GLP-1 Patches Work? The Molecule Is Too Big
- Do Wisconsin and Minnesota Medicaid Cover Wegovy or Zepbound? The Two States Compared
- Does a Lifetime of It Change Anything?
- Does a Sauna Burn Calories? Sweat Is Water, and It Comes Back
- Does Aetna Cover Zepbound and Wegovy? It Depends on Your Aetna Drug List
- Does Alabama Medicaid Cover Wegovy or Zepbound? The Three PA Routes
- Does Alaska Medicaid Cover Wegovy or Zepbound? Heart, Liver and Sleep Apnea Rules
- Does Arizona Medicaid (AHCCCS) Cover Ozempic, Wegovy or Zepbound?
- Does Arkansas Medicaid Cover Wegovy or Zepbound? The Three Routes That Remain
- Does Blue Cross Cover Zepbound and Wegovy? Four Blue Plans, Four Different Answers
- Does Cigna Cover Zepbound and Wegovy? Express Scripts Covers the Pen, Not the KwikPen
- Does CLA Help With Weight Loss? What the Trials and FDA Records Show
- Does Connecticut HUSKY Cover Wegovy or Zepbound? Forms, Tests and the 2025 Law Change
- Does DC Medicaid Cover Wegovy or Zepbound? Fee-for-Service and Both Plans Compared
- Does Delaware Medicaid Cover Wegovy and Zepbound? Yes, With a Health-Condition Rule
- Does Florida Medicaid Cover Wegovy or Zepbound? No Published Route as of November 2026
- Does Georgia Medicaid Cover Wegovy or Zepbound? No, Except a Narrow Teen Route
- Does Hawaii Med-QUEST Cover Wegovy or Zepbound? Not for Weight Loss
- Does Idaho Medicaid Cover Wegovy or Zepbound? Obesity Drugs Are Excluded by Rule
- Does Illinois Medicaid Cover Ozempic, Wegovy or Zepbound? Diabetes Yes, Weight Loss No
- Does Indiana Medicaid Cover Zepbound or Wegovy? The Four PA Routes
- Does Iowa Medicaid Cover Wegovy? One Form, Three Routes, No Weight Loss
- Does Kaiser Cover Zepbound and Wegovy? Wegovy First, Zepbound Rarely
- Does Kansas Medicaid Cover Wegovy? KanCare's Weight-Loss Rules for 2026
- Does Kentucky Medicaid Cover Wegovy or Zepbound? Strict Routes, No Weight Loss
- Does Louisiana Medicaid Cover Wegovy or Zepbound? Act 898 and Today's Rules
- Does Lumen Help With Weight Loss? No Controlled Trial Says So
- Does MaineCare Cover Wegovy or Zepbound? Heart, Liver and Sleep Apnea Rules
- Does Maryland Medicaid Cover Wegovy or Zepbound? Chapter 866 and the Current Rules
- Does MassHealth Cover Wegovy or Zepbound? The July 3, 2026 Cutoff and What Remains
- Does Medi-Cal Cover Wegovy or Zepbound? Not for Adult Weight Loss Since January 2026
- Does Medicaid Cover Ozempic and Wegovy? Same Molecule, Different Answers
- Does Medicaid Cover Zepbound? The Federal Rule and the Sleep Apnea Indication
- Does Michigan Medicaid Cover Wegovy or Zepbound? BMI 40 and the Five-Drug Rule
- Does Mississippi Medicaid Cover Wegovy and Zepbound? Coverage, Criteria and Who Stays On
- Does Missouri Medicaid Cover Zepbound and Wegovy? MO HealthNet's GLP-1 Rules
- Does Montana Medicaid Cover Wegovy or Zepbound? Heart, MASH and Sleep Apnea Rules
- Does Nebraska Medicaid Cover Wegovy or Zepbound? Heritage Health GLP-1 Rules
- Does Nevada Medicaid Cover Wegovy or Zepbound? Heart, MASH and Sleep Apnea Routes
- Does New Hampshire Medicaid Still Cover Wegovy or Zepbound? The 2026 Rules
- Does New Mexico Medicaid Cover Wegovy? Why Phentermine Is In and GLP-1s Are Out
- Does New York Medicaid Cover Wegovy or Zepbound? NYRx's BMI 40 and Lifetime Limits
- Does NJ Medicaid Cover Zepbound or Wegovy? NJ FamilyCare's GLP-1 Rules
- Does North Dakota Medicaid Cover Wegovy? The Ozempic-First Routes Explained
- Does Ohio Medicaid Cover Wegovy or Zepbound? What the Unified Drug List Says
- Does Oklahoma Medicaid Cover Wegovy? SoonerCare's GLP-1 Rules for 2026
- Does Ozempic Cause Erectile Dysfunction? What the Evidence Shows
- Does Ozempic Make You Pee More? GLP-1 Drugs, Urination and Thirst
- Does Ozempic or Mounjaro Cause Anxiety? What the Trials and Labels Show
- Does Ozempic Slow Your Metabolism? What the Measurements Show
- Does Pennsylvania Medicaid Cover Wegovy or Zepbound? What Ended in January 2026
- Does Semaglutide Slow Aging? What the Longevity Evidence Shows
- Does Spirulina Help With Weight Loss? What Small Trials Found
- Does TennCare Cover Wegovy and Zepbound? Yes, for Obesity, With a 5% Renewal Test
- Does Texas Medicaid Cover Wegovy or Zepbound? Exclusions and the Age-45 Rule
- Does the Oregon Health Plan Cover Wegovy or Zepbound? OHP's 2026 GLP-1 Rules
- Does UnitedHealthcare Cover Zepbound and Wegovy? Only If Your Employer Opted In
- Does Vaping or Nicotine Cause Weight Loss? What Smokers' Data Show
- Does Vermont Medicaid Cover Wegovy or Zepbound? Heart, MASH and Sleep Apnea Only
- Does Washington Apple Health Cover Wegovy or Zepbound? The Three Medical Routes
- Does Weight Loss Fake Kidney Numbers?
- Does Wyoming Medicaid Cover Wegovy or Zepbound? The Sleep Apnea, MASH and Heart Routes
- Does Your GLP-1 Wear Off Before the Next Dose?
- Drinking on a GLP-1: What the Label Actually Says
- Dry Mouth on a GLP-1: Three Published Cases, and What to Tell Your Dentist
- DSIP: A Sleep Peptide Named in 1977, With No Known Receptor
- Eating Too Little on a GLP-1: What the Deficiency Data Show
- Eight Things Patients Said
- Elamipretide (SS-31): The Phase 3 Trial That Missed Both Endpoints
- Elecoglipron: A Second Oral GLP-1 Pill in Phase 2
- Eloralintide and Petrelintide: The Amylin-Only Drugs in Phase 3
- Endoscopic Sleeve vs Surgical Sleeve: Less Weight Lost, Fewer Complications
- Epitalon Dosage and Courses: What the Studies Used and What HHS Covers
- Epitalon: What the Evidence Shows, and What FDA Found
- Every Other Week: Stretching the Interval
- Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
- Exercise Plus a GLP-1: What Each One Actually Changes
- Fat-to-Muscle Ratio: Surgery Versus Drugs
- FDA Warning Letters to Peptide Sellers: What FDA Has Cited, 2023 to 2026
- FDA-Approved Peptides: The Verified List, and What Is Not on It
- Feeling Cold and Night Sweats on a GLP-1: What the Labels and Studies Show
- Five Clicks Instead of a Quarter Milligram
- Five Hundred Calories at One Lunch
- Food Noise: A Patient’s Word That Now Has a Questionnaire
- Foundayo (Orforglipron) Side Effects: Rates by Dose, Dropouts and Interactions
- Foundayo (Orforglipron): the GLP-1 Pill With No Fasting Rule
- Foundayo Cost: Orforglipron Price by Dose, Insurance and Medicare
- FUPA and GLP-1 Weight Loss: What Shrinks It and What Does Not
- Gabapentin and Pregabalin Weight Gain: What the Labels Show, and Where a GLP-1 Fits
- Garcinia Cambogia: What the Weight-Loss and Liver Evidence Shows
- Generic GLP-1s: Eleven for Liraglutide, and None You Can Buy for Semaglutide
- Genetics Caused It, and the Drug Still Worked
- GHK-Cu: What the Evidence Shows for Skin, Hair and Injections
- GLP-1 Allergic Reactions and Anaphylaxis: What the Labels and Cases Show
- GLP-1 Booster Supplements by Brand: What Is Inside and What Was Tested
- GLP-1 Bowel Obstruction and Ileus: Label Warning and Evidence Review
- GLP-1 Diarrhea: Why It Doesn't Follow the Dose, and What Has Actually Been Tested
- GLP-1 Drugs After 65: Strength, Not Just Weight
- GLP-1 Drugs After Menopause: The Group Taking Them Most, Studied Least
- GLP-1 Drugs After Spinal Cord Injury: Three People Treated, Two Not
- GLP-1 Drugs and Addiction: A Huge Signal, and a Trial That Missed
- GLP-1 Drugs and Asthma Risk: Read the Severity Column, Not the Headline
- GLP-1 Drugs and Blood Pressure: How Much It Falls, and What Happens When You Stop
- GLP-1 Drugs and Bone: Fracture Risk, Density and What Was Measured
- GLP-1 Drugs and Cholesterol: What Happens to LDL, HDL and Triglycerides
- GLP-1 Drugs and Eating Disorders: Two Questions, One Studied
- GLP-1 Drugs and Headache: A Side Effect, and a Treatment
- GLP-1 Drugs and Hidradenitis Suppurativa: Early Studies, No Trial
- GLP-1 Drugs and HIV-Associated Lipohypertrophy: The Randomized Evidence
- GLP-1 Drugs and Insulin Resistance: What the HOMA-IR Data Show
- GLP-1 Drugs and Kidney Stones: What the Labels and Studies Show
- GLP-1 Drugs and Lipedema: What Semaglutide and Tirzepatide Studies Show
- GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk
- GLP-1 Drugs and Migraine: Liraglutide, Semaglutide and Tirzepatide Evidence
- GLP-1 Drugs and Opioid Use Disorder: What the Records Data Shows
- GLP-1 Drugs and Parkinson's Disease: What LIXIPARK and Exenatide-PD3 Showed
- GLP-1 Drugs and Quitting Smoking: What the Trials Actually Tested
- GLP-1 Drugs and Rheumatoid Arthritis: One Study, and What It Cannot Tell You
- GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026
- GLP-1 Drugs and the Gut Microbiome: What 38 Studies Could Not Agree On
- GLP-1 Drugs and Type 1 Diabetes: The Label Says Unevaluated. Three Trials Disagree.
- GLP-1 Drugs and Your Breasts: Size, Pain, Mammograms and Cancer Risk
- GLP-1 Drugs and Your Kidneys: Protective Over Years, Risky Over Days
- GLP-1 Drugs for PCOS: Eleven Trials, and Two Analyses That Disagree
- GLP-1 Drugs for Prediabetes: What Semaglutide and Tirzepatide Did to Diabetes Risk
- GLP-1 Drugs in Cushing's Syndrome: Weight Down, Cortisol Unchanged
- GLP-1 Drugs in Teenagers: What 18 Trials Show
- GLP-1 Drugs, Diabetic Foot Ulcers and Blood Flow to the Foot
- GLP-1 Drugs, Testosterone and Male Fertility: Where the Evidence Splits
- GLP-1 Eye Risks: Diabetic Retinopathy and NAION Are Not the Same Thing
- GLP-1 Hair Loss and Muscle Loss: What Was Measured
- GLP-1 Overdose: What Happens and What to Do
- GLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted
- GLP-1 Patient Assistance Programs: What Novo Nordisk and Lilly Cares Give Free
- GLP-1 Prior Authorization: the Criteria, the Clock, the Appeal
- GLP-1 Side Effects in Women vs Men: What the Trials Measured
- GLP-1 Skin Sensitivity, Rash and Itching: What the Labels Record
- GLP-1 Supplements: Do Berberine, Lemon Extract and Probiotics Work?
- GLP-1 Telehealth Cancellation and Refund Policies
- GLP-1 Thyroid Cancer Risk: What the Boxed Warning Actually Says
- GLP-1s After a Kidney Transplant
- GLP-1s and Antipsychotic Weight Gain: A Trial Cut Short
- GLP-1s and Atrial Fibrillation: Reading a 42% Headline
- GLP-1s and Autoimmune Thyroiditis: An Association, and the Reason to Doubt It
- GLP-1s and Cancer: The Randomized Answer
- GLP-1s and Cancer: What the Cohorts Actually Show
- GLP-1s and Daytime Sleepiness
- GLP-1s and Epilepsy Risk
- GLP-1s and Fatty Liver: What the Phase 3 Trial Showed
- GLP-1s and Hormonal Birth Control: Which Labels Carry the Warning
- GLP-1s and Inflammatory Bowel Disease
- GLP-1s and Sex Drive: What Ozempic and Mounjaro Do to Libido in Men and Women
- GLP-1s and Worsening Mental Illness
- GLP-1s and Your Other Medications: What Actually Interacts
- GLP-1s During Ramadan: What the Four Studies Actually Tested
- GLP-1s in People Being Treated for Cancer
- GLP-1s, Pneumonia and Sepsis: A Better-Built Cohort
- GLP-1s, Pregnancy and Trying to Conceive: What the Labels Say
- GLP-1s, Travel and Time Zones
- Glutathione: What the Evidence Shows for Pills, IV Drips and Injections
- Green Tea Extract for Weight Loss: A Small Effect and a Liver Risk
- Gymnema Sylvestre: A Meta-Analysis With No Control Group
- Handgrip Strength and Sarcopenic Obesity
- HCG, B12 and Lipotropic Shots: What the Labels and the FDA Say
- Hexarelin: What the Human Studies Show, and Why It Is Not on FDA's Lists
- HHS Peptide Compounding Policy (October 2026): The Six Peptides and Ten Conditions
- Holding a GLP-1 Before Endoscopy or Surgery: What the Trial Found
- How Far You Can Walk
- How Long Can Zepbound, Wegovy and Ozempic Be Out of the Fridge?
- How Long Do Semaglutide and Tirzepatide Side Effects Last?
- How Long Do Zepbound, Wegovy and Other GLP-1s Stay in Your System?
- How Long Is the Evidence, Actually?
- How Many People to Treat to Help One
- How Many Units Is Your GLP-1 Dose? It Depends on the Vial
- How Much Does Compounded Semaglutide Cost? What Drives the Number
- How Much GLP-1 Prices Actually Vary
- How to Check a Seller's Review Score in 60 Seconds
- How to Get a GLP-1 Covered by Insurance
- How to Get a GLP-1 Prescription
- How to Join a GLP-1 Clinical Trial: Finding a Real Obesity Drug Study
- How to Read a Peptide Certificate of Analysis (and What It Cannot Prove)
- How to Take the Wegovy Pill: Water, Timing, Doses and Missed Pills
- How to Tighten Skin After Weight Loss: Radiofrequency, Ultrasound and Surgery
- How to Trust an Observational Study
- How to Verify an Online GLP-1 Pharmacy: Six Public Checks
- How Zepbound Works: Tirzepatide's Two Receptors, Appetite and Fat Loss
- Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ
- Intermittent Fasting on a GLP-1: What Has Been Tested and What Has Not
- Ipamorelin vs Sermorelin: Two Growth Hormone Peptides With Opposite FDA Records
- Is Compounded Tirzepatide Safe? What FDA Has Actually Reported
- Is It Just the Weight Loss?
- Is Microdosing Actually Cheaper? We Checked All 556 Sellers
- Is Ozempic a Peptide? What Semaglutide and Tirzepatide Are Made Of
- Is Ozempic Available Over the Counter? No GLP-1 Is, and What Is Sold Instead
- Is Rybelsus Being Discontinued? What Happened and the Ozempic Pill Switch
- Is the Vial You Received What the Label Says?
- Is There a Best Time of Day to Inject a GLP-1?
- Is There a Tirzepatide Pill? What Sellers Ship
- Is Tirzepatide Anti-Inflammatory, or Just Slimming?
- Is Zepbound a Semaglutide? Brand Names vs Molecules
- Januvia and Ozempic Together: Why Doctors Usually Stop the Januvia
- Jardiance and Farxiga for Weight Loss: How Much, and Why It Stops
- Jardiance or Farxiga With Ozempic or Mounjaro: Taking an SGLT2 and a GLP-1
- Joint Pain, Back Pain and Aches on a GLP-1: What the Trials Counted
- Judged Worse Than Not Losing Weight
- Kisspeptin: What the Human Studies Show, and What They Don't
- KPV Capsules and Cream: Oral and Topical KPV Under the HHS Peptide Policy
- KPV: What the Evidence Shows, and What FDA Found
- L-Carnitine Injections for Weight Loss: What the Evidence Shows
- Less Than Half Are Still Taking It
- Levothyroxine and a GLP-1: Why Your Thyroid Dose May Need to Come Down
- Lifestyle Plus the Drug
- LL-37: Thousands of Papers, No Human Trials
- Losing Fast Early: What It Predicts
- Losing Weight Predicted More Heart Attacks
- Low-Calorie Snacks: What the Evidence Says, and What Changes on a GLP-1
- Many People Never Reach the Dose
- MariTide (Maridebart Cafraglutide): What the Evidence Shows
- Mazdutide: What the Trials Show, and Why It Is Approved Only in China
- Medicaid Managed Care and Wegovy: Why Your Plan Often Doesn't Set the GLP-1 Rule
- Medicare and GLP-1s: the $50 Bridge That Opened in July
- Melanotan and the Approved Drug It Is Not
- Metformin and a GLP-1 Together: The Risk Is Not the One People Expect
- Metformin for Weight Loss: How Much You Lose, With or Without Diabetes
- Metformin vs GLP-1 for Longevity: The TAME Trial Has Not Started
- Microdosing a GLP-1: What Evidence Exists
- MK-677 vs HGH: An Unapproved Pill and a Restricted Prescription Hormone
- MK-677: A Real Trial in Eight People, and a Liver Report
- More Effect Without More Side Effects
- MOTS-c Dosage and Side Effects: What Has Been Tested in People
- MOTS-c: What the Evidence Shows, and What FDA Found
- Mounjaro Alternatives: What Costs Less and What You Give Up
- Mounjaro Heart Protection: What SURPASS-CVOT Found and What FDA Approved
- Muscle Loss: Drug Versus Dieting
- Muscle Volume Versus Muscle Function on a GLP-1
- NAD+ and Longevity: What the NMN and NR Trials Actually Show
- NAD+ Injections: What the Evidence Shows
- NAD+ vs NMN: Drips and Injections vs the Oral Precursor
- Newer Is Not Stronger
- Normal Blood Sugar Is Not Remission
- North Carolina Medicaid Covers Wegovy and Zepbound. The State Health Plan Does Not.
- Not Taking It and Not Tolerating It
- Nutrition Drinks Alongside a GLP-1
- One Injection Instead of Twenty-Eight
- One Trial on Fertility
- Ozempic and Gastroparesis: How Real Is “Stomach Paralysis”?
- Ozempic and Penis Size: What Weight Loss Changes and What It Does Not
- Ozempic and Smell: Sensitivity, Food Aversion, Urine and Body Odor
- Ozempic and the Vagina: Dryness, Odor and Yeast Infections
- Ozempic Brain Fog: What the Labels, Trials and Reports Show
- Ozempic Butt: What Large Weight Loss Changes in the Buttocks
- Ozempic Dreams and Nightmares: What the Evidence Shows
- Ozempic Face: What Imaging Studies Measured, and What Treats It
- Ozempic Feet and Hands: Swelling, Heel Pain, Tingling and Numbness
- Ozempic Pill (Ozempic Tablets): Doses, How to Take It, Cost and the Wegovy Pill
- Ozempic Vulva: What the Evidence Shows About Fat Loss and the Labia
- Ozempic, Mounjaro and Tinnitus: What the Hearing Evidence Shows
- Ozempic, Mounjaro and Your Period: Late, Heavy or Spotting on a GLP-1
- Ozempic, Wegovy and Zepbound While Breastfeeding: What the Labels Say
- Pemvidutide: What the Evidence Shows
- Peptide Blood Work: Which Labs a Label Requires and Which Are Sold as a Package
- Peptides for Hair Growth: GHK-Cu and Other Serums Against Minoxidil and Finasteride
- Peptides for Muscle Growth: What Human Trials Show for MK-677, CJC-1295 and More
- Peptides for Weight Loss: Every One Sold, Ranked by Human Evidence
- Peptides in Skincare: What Matrixyl, Argireline and Copper Peptide Trials Show
- Peptides Without Needles: What Oral, Nasal and Topical Forms Deliver
- Phentermine and a GLP-1 Together: What the Labels and Trials Show
- Phentermine vs Ozempic, Wegovy and Zepbound: Is Phentermine a GLP-1?
- Plant-Based Protein on a GLP-1: What Closes the Gap, and Why the Drug Widens It
- Protein Targets and the Lab Panel
- PT-141 (Bremelanotide): What the Evidence Shows
- Raspberry Ketones for Weight Loss: Never Tested Alone in People
- Real, and Below the Threshold
- Red Light Therapy for Weight Loss: Cleared for Inches, Never for Pounds
- Research Use Only vs Compounded Peptides: What the Label Means Legally
- Retatrutide Dosing: The Doses, Starting Dose and Escalation Used in the Trials
- Retatrutide Price and Release Date: What Is Known
- Retatrutide Side Effects: What the TRIUMPH Trials Report, Dose by Dose
- Retatrutide: What the Evidence Actually Shows
- Retatrutide's Phase 3, and the Gray Market
- Rhode Island Medicaid and GLP-1s: Weight-Loss Coverage Ended October 1, 2026
- Rybelsus for Weight Loss: How Much Weight People Lose, and Why It's Less
- Seizures When You Already Have Epilepsy
- Selank: Real Clinical Trials, One Country, No Replication
- Semaglutide and Alzheimer's: The Trials Came Back Negative
- Semaglutide and Days Spent in Hospital
- Semaglutide and Knee Osteoarthritis: The Number Behind the Headline
- Semaglutide and Motivation
- Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage
- Semaglutide for Alcohol Use Disorder: Read the Placebo Arm
- Semaglutide Week by Week: When the Weight Actually Comes Off
- Semax vs Selank: Two Russian Nasal Peptides, and Only One Is Now Covered
- Semax: Human Brain Imaging, No Cognitive Outcome
- Sermorelin for Weight Loss: Zero Trials, Real History
- Sermorelin vs Tesamorelin: The Discontinued GHRH Analog and the Approved One
- Sleep and Mood on a GLP-1: What Improved, and What Did Not Predict It
- South Carolina Medicaid and Weight-Loss GLP-1s: What Was Dropped and What Remains
- South Dakota Medicaid and Wegovy or Zepbound: No Weight-Loss Coverage, Three PA Routes
- Statins and a GLP-1: Taking Lipitor or Crestor With Ozempic or Mounjaro
- Stomach Pain on a GLP-1: What Is Expected and What Is a Warning Sign
- Stopping as a Clinical Transition
- Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off
- Stopping Tirzepatide (Zepbound): Weight Regain, Side Effects and Cold Turkey
- Stretching Doses to Save Money
- Sublingual Semaglutide Drops: What the Evidence Shows
- Surgery Versus GLP-1 Drugs: Reading an Indirect Comparison
- Survodutide: What the Phase 3 Evidence Shows
- Switching Between GLP-1 Drugs
- Taste Got Better, Not Worse
- TB-500 Side Effects and Dosing: Whose Safety Data Are They?
- TB-500 vs GHK-Cu: A Covered Injection and an Uncovered Copper Peptide
- TB-500: What the Evidence Shows, and What FDA Found
- Tesamorelin for Weight Loss? Read Its Own Label
- Tesofensine for Weight Loss: What the Trials Showed and Why It Isn't Approved
- The Add-On Menu
- The Biggest Number Is the Weakest
- The BMI Threshold Is Not Universal
- The Cardiovascular Cost of Stopping
- The Cochrane Verdict, and Who Funded the Evidence
- The Cost-Effectiveness Case, and What Is Inside It
- The Day the Balloon Comes Out
- The Diet Advice Nobody Has Tested
- The Dose That Stopped Helping
- The Drugs Nobody Writes About
- The Drugs That Are Not Here Yet
- The Fat Pads in Your Ears
- The First Pill-Versus-Pill Trial
- The Gelatin Trick for Weight Loss: What the Trials Found
- The Genetic Test That Isn't Ready
- The Genetics Are Real, and Small
- The GLP-1 Terms You Agree To at Checkout
- The Group That Lost Least Did Best
- The Head-to-Head, and What It Settles
- The Line Is Drawn by Surgery
- The Low-FODMAP Diet on a GLP-1: What It Does for IBS and What Is Untested
- The Mediterranean Diet Trial That Measured Heart Attacks, Not Weight
- The Mental Health Score That Did Not Move
- The Old Cheap Drug Keeps Winning
- The One Place People Felt Better
- The Peptide Menu: What Has Human Trials and What Does Not
- The Pink Salt Trick: What It Does and Why It Is Not a Natural Mounjaro
- The Statistic That Asks If Groups Differ
- The Thing That Makes Regain Inevitable
- The Thyroid Test Nobody Reordered
- The Top Dose Keeps Not Being Worth It
- The Weight Comparison Used 257 People
- Three Domains Improved, Then One
- Thymosin Alpha 1 (Thymalfasin): What the Evidence Shows
- Tirzepatide and Longevity: What the Death and Aging Data Show
- Tirzepatide in Ten- to Seventeen-Year-Olds
- Tirzepatide Long-Term Side Effects: Where the Evidence Stops
- Tirzepatide Versus Semaglutide on Mood
- Tirzepatide vs Dulaglutide: A Real Head-to-Head
- Tirzepatide Week by Week: What the SURMOUNT Trials Recorded
- Tirzepatide With Glycine, B6 or Niacinamide
- TRICARE, FEHB and PSHB: Who Covers Wegovy and Zepbound in 2026
- Trulicity for Weight Loss: How Much at Each Dose
- TrumpRx GLP-1 Prices: What Wegovy, Ozempic, Zepbound and Foundayo Cost
- Two Studies, One Comparison, Two Answers
- Uric Acid and Two Answers
- Utah Medicaid and Wegovy or Zepbound After the Weight-Loss Pilot Ended
- We Know What They Do, Not What They're Worth
- We Read FDA's Register of Compounding Facilities. 43 of 100 Have Never Been Inspected.
- Wegovy 7.2 mg: What the Higher Dose Actually Costs
- Wegovy Pill Cost: Every Dose and Every Way to Pay
- Wegovy Pill Side Effects: What the Tablet Label Reports
- Wegovy Pill vs Injection: Is the Pill as Good as the Shot?
- West Virginia Medicaid and Wegovy or Zepbound: The Heart, Liver and Sleep Apnea Routes
- What 262 Trials Say Together
- What 519 GLP-1 Signup Funnels Look Like
- What a LegitScript Badge Tells You, and What It Doesn't
- What a Low Dose Actually Does
- What a Plateau Actually Means
- What Are Peptides? What They Do in the Body, and Which Are Actual Drugs
- What Cannot Legally Be Compounded, and Who Is Selling It Anyway
- What Changed in the Teenagers' Bloodwork
- What GIP Does on Its Own
- What Happens When You Stop a GLP-1: What the Withdrawal Trials Measured
- What Instagram Leaves Out
- What Is in a Compounded GLP-1 Vial: How to Read the Label
- What Is NAD+? What It Does in the Body and What Supplements Claim
- What Is Peptide Therapy? Approved Drugs, Compounded Peptides and Research Vials
- What Is Phentermine? Uses, Label Limits and How It Compares
- What Makes a Telehealth GLP-1 Prescription Legitimate
- What People Actually Do After Stopping
- What Sets the Price of Semaglutide: The Routes and the Four Variables
- What the FDA's GLP-1 Warning Letters Say About This Market
- What These Drugs Do Outside a Trial
- What These Hormones Do Without a Pancreas
- What Tripling the Dose Buys
- What We Can and Cannot Verify
- What Your Doctor Cannot See
- When a Hazard Ratio Is Too Good
- When Is It Safe to Have the Skin Removed?
- When Pooling Studies Hides the Answer
- When the Appetite Center Is Damaged
- When the Primary Endpoint Fails and a Secondary Doesn't
- When to Take Berberine: Before Meals, at Night and the Doses Tested
- When Weight Comes Back After Bariatric Surgery: What a GLP-1 Adds
- Where the Evidence Is Strongest
- Where to Inject a GLP-1, and Why Rotation Matters
- Which Drugs Are GLP-1s? Mounjaro, Trulicity, Phentermine and 25 More, Checked
- Which GLP-1 Has the Worst Side Effects?
- Which GLP-1s Can Be Compounded? The FDA Shortage and Bulks-List Rules
- Which Zepbound Dose Works Best? 5, 10 and 15 mg Compared in the Trials
- Who Actually Runs Your GLP-1 Brand
- Who Loses More Weight on a GLP-1?
- Who Responds in the Real World
- Who Tells You How Your GLP-1 Ships?
- Who Was Actually in the Trials
- Why a GLP-1 Raises Your Heart Rate, and When Palpitations Matter
- Why Combination Therapy Fails in Practice
- Why Compounded Semaglutide Is Mixed With B12
- Why GLP-1 Drugs Make You Tired, and What Nobody Has Studied
- Why the Appetite Comes Back
- Xanthelasma: Heart Risk, Cholesterol, Weight Loss and Removal
- Zepbound for Sleep Apnea: What SURMOUNT-OSA Actually Found
- Zepbound Vials and Syringes: How the Vial Works and What It Costs
How we work
A figure in an investigation was read off the seller’s own page on a recorded date. A clinical statement traces to PubMed, an FDA document, or the trial paper itself, and never to a press release, a listicle or another comparison site. Where two sources disagree we say so on the page instead of picking the tidier one. An article gets revisited when the evidence under it moves, though we will not pretend that happens the instant a study lands.
Nothing here is a recommendation to take a particular drug, and none of it can weigh your history the way a clinician can. Take the decision to one. How we rate sellers →